Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VMD-928 |
| Synonyms | |
| Therapy Description |
VMD-928 is an NTRK1 inhibitor that may have anti-tumor activity (Journal of Clinical Oncology 37, no. 15_suppl, Abstract TPS3146). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VMD-928 | VMD928|VMD 928 | TrkA Receptor Inhibitor 8 | VMD-928 is an NTRK1 inhibitor that may have anti-tumor activity (Journal of Clinical Oncology 37, no. 15_suppl, Abstract TPS3146). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |